News
CHICAGO-- (BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, ...
In order to expand the dialogue on the directions of pharmaceutical assistance in the Unified Health System (SUS), the State Health Department of Pará (Sespa) participates in the III Pará Congress on ...
Teva Pharmaceutical Industries Ltd. announced the final analysis of the PEARL Phase 4 study at the European Academy of Neurology Congress 2025, confirming that AJOVY (fremanezumab) is effective in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results